Effect of IMOD™ on the inflammatory process after acute ischemic stroke: a randomized clinical trial
Authors:
- Mehdi FarhoudiMFMehdi Farhoudi
- Mahdi Najafi-NesheliMNMahdi Najafi-Nesheli
- Mazyar HashemilarMHMazyar Hashemilar
- Ata MahmoodpoorAMAta Mahmoodpoor
- Ehsan SharifipourESEhsan Sharifipour
- Behzad BaradaranBehzad Baradaran
- Aliakbar TaheraghdamATAliakbar Taheraghdam
- Daryoush Savadi-OskoueiDSDaryoush Savadi-Oskouei
- Homayoun Sadeghi-BazarganiHSHomayoun Sadeghi-Bazargani
- Elyar Sadeghi-HokmabadiESElyar Sadeghi-Hokmabadi
- Hosein AkbariHAHosein Akbari
- Reza RikhtegarRRReza Rikhtegar
Open Access
- 20 March 2013
- journal article
- Published by Springer Nature in DARU Journal of Pharmaceutical Sciences
- Vol. 21 (1) , 26
Abstract
Considering the role of inflammation in acute cerebrovascular accidents, anti-inflammatory treatment has been considered as an option in cerebrovascular diseases. Regarding the properties of Setarud (IMOD™) in immune regulation, the aim of the present study was to evaluate the role of this medication in treating patients with acute ischemic stroke. In this randomized clinical trial, 99 patients with their first ever acute ischemic stroke were divided into two groups of IMOD™ (n = 49) and control (n = 50). The control group underwent routine treatment and the intervention group underwent routine treatment plus daily intermittent infusion of IMOD™ (250mg on the first day and then 375mg into DW5% serum during a 30-minute period for 7 days). The serum levels of inflammatory markers were evaluated on the first day (baseline) and on 4th and 7th days. Data were analyzed and the results were compared. 58 males (58.6%) and 41 females (41.4%) with a mean age of 67.00 ± 8.82 years, who had their first ever stroke attack, were enrolled in this trial. Treatment with IMOD™ showed a decreasing trend in IL-6 levels compared to the control group (p = 0.04). In addition, the treatment resulted in the control of increasing serum levels of hsCRP after 7 days compared to the control group (p = 0.02). There was an insignificant decrease in TNF-α and IL-1 levels in the IMOD™ group. Considering the prominent role of inflammation after an ischemic cerebral damage, it appears that treatment with IMOD™ improves the inflammatory profile. Therefore, IMOD™ (Setarud) might be considered as a therapeutic option in the acute ischemic stroke. However, future studies are necessary on its long-term results and clinical efficacy.Keywords
This publication has 41 references indexed in Scilit:
- Positive effect of septimeb™ on mortality rate in severe sepsis: a novel non antibiotic strategyDARU Journal of Pharmaceutical Sciences, 2012
- Brain-Immune Interactions and Ischemic StrokeArchives of Neurology, 2012
- Neuroprotection by inhibiting the c-Jun N-terminal kinase pathway after cerebral ischemia occurs independently of interleukin-6 and keratinocyte-derived chemokine (KC/CXCL1) secretionJournal of Neuroinflammation, 2012
- Interleukin-1 and Stroke: Biomarker, Harbinger of Damage, and Therapeutic TargetCerebrovascular Diseases, 2011
- Systemic inflammatory challenges compromise survival after experimental stroke via augmenting brain inflammation, blood- brain barrier damage and brain oedema independently of infarct sizeJournal of Neuroinflammation, 2011
- Efficacy of Setarud (IMOD TM ), a novel electromagnetically-treated multi-herbal compound, in mouse immunogenic type-1 diabetesArchives of Medical Science, 2010
- Admission C – reactive protein after acute ischemic stroke is associated with stroke severity and mortality: The 'Bergen stroke study'BMC Neurology, 2009
- Systemic infection, inflammation and acute ischemic strokeNeuroscience, 2009
- The inflammatory response in strokeJournal of Neuroimmunology, 2007
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke, 1993